SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (20)
2024
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
2022
-
A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol
BMC Psychiatry, Vol. 22, Núm. 1
-
The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0
Supportive Care in Cancer, Vol. 30, Núm. 8, pp. 6745-6754
2021
-
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Scientific Reports, Vol. 11, Núm. 1
-
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice
Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
-
Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations
Drugs, Vol. 80, Núm. 2, pp. 131-146
-
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724
2019
2018
-
Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)
Breast Cancer Research and Treatment
-
Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification
Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852
-
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634
2017
-
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
PLoS ONE, Vol. 12, Núm. 10
-
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
Breast Cancer Research and Treatment, Vol. 162, Núm. 1, pp. 181-189
2015
-
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy
Clinical Cancer Research, Vol. 21, Núm. 17, pp. 3995-4003
2014
-
Chemobrain: ¿podemos hablar de un daño cerebral adquirido por quimioterapia?
Trauma (Spain), Vol. 25, Núm. 3, pp. 143-149
-
Náuseas y vómitos inducidos por quimioterapia antineoplásica. ¿Perceptión o realidad?
Revisiones en Cancer, Vol. 28, Núm. 4, pp. 135-145
2012
-
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies
Breast Cancer Research and Treatment, Vol. 134, Núm. 2, pp. 583-593
2011
-
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136
2010
-
Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600